Prof Michael Herbst of CANSA was interviewed on SABC TV on the question of the exorbitant costs of cancer medications and the announcement by the Competition Commission of its probe into the pricing of several cancer medicines in South Africa.
CELGENE FLAGGED
For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene...